glucosamine has been researched along with Diabetes Mellitus, Type 2 in 81 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (12.35) | 18.7374 |
| 1990's | 31 (38.27) | 18.2507 |
| 2000's | 34 (41.98) | 29.6817 |
| 2010's | 2 (2.47) | 24.3611 |
| 2020's | 4 (4.94) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, Z; Fang, X; Hou, Y; Xu, C; Yang, H | 1 |
| Berenice, FR; Itandehui Belem, GV; Jesús, HJ; Miguel Ángel, PA; Pedro Antonio, HC | 1 |
| Heianza, Y; Li, X; Li, Y; Liang, Z; Ma, H; Qi, L; Sun, D; Zhou, T | 1 |
| Fan, R; Hao, Y; Hu, J; Kang, J; Li, Y; Liu, R; Liu, X; Mao, R; Xu, M; Zhu, N | 1 |
| Ji, DF; Li, YG; Lin, TB; Lv, ZQ; Zhong, S | 1 |
| Li, Y; Tong, N; Zhang, X | 1 |
| Drent, ML; Hoenderdos, EB; Jonker, JJ; Tollefsen, AT; van der Veen, EA; van Heusden, FH | 1 |
| Horowitz, M; Lee, A; Morley, JE; Patrick, P; Wishart, J | 1 |
| Weissman, P | 1 |
| Artés, M; Benito, P; Faure, E; García-Mayor, R; López, JS; Mesa, J; Pallardo, LF; Puig-Domingo, M; Ravella, R | 1 |
| Chawla, S; Takiya, L | 1 |
| Fischer, S; Hanefeld, M | 1 |
| Scheen, AJ | 1 |
| Albright, A; Harris, MD; Scroggie, DA | 1 |
| Malik, T; Trence, DL | 1 |
| Aller, R; Conde Valentín, R; de Luis Román, DA; del Pozo García, E; Romero Bobillo, E | 1 |
| Haslbeck, M; Jakob, S; Kellerer, M; Linn, T | 1 |
| Jain, RK; McCormick, JC | 1 |
| Fehmann, HC | 4 |
| Akkermans, RP; Lucassen, PL; Rutten, GE; Van de Laar, FA; Van de Lisdonk, EH; Van Weel, C | 1 |
| Hayashi, I; Kuboyama, N; Yamaguchi, T | 1 |
| Brandes, L; Marshall, PD; Poddar, S; Tweed, EM | 1 |
| Muniyappa, R; Quon, MJ | 1 |
| Albert, SG; Haas, MJ; McPherson, T; Mooradian, AD; Oiknine, RF; Parseghian, S | 1 |
| Kang, Y; Kim, Y; Kwon, H; Park, J | 1 |
| Choi, MS; Jeon, SM; Jung, UJ; Jung, YM; Lee, MK; Lee, YH; Yeo, J | 1 |
| Bozza, M; Corgiat-Mansin, L; Cravero, F; Giorda, C; Marena, S; Pagano, G; Rossi, CM | 1 |
| Balkan, B; Dunning, BE | 1 |
| Branolte, JH; Kingma, PJ; Menheere, PP; Nieuwenhuijzen Kruseman, AC; Sels, JP; Wolffenbuttel, BH | 1 |
| Coniff, RF; Hoogwerf, BJ; Johnston, PS; Krol, A; Pi-Sunyer, FX; Santiago, JV | 1 |
| DeBouno, JF; Michaelis, OE; Tulp, OL | 1 |
| Johnson, AB; Taylor, R | 1 |
| Campillo, JE; Martinez, IM; Nieto, M; Ropero, MF; Tormo, MA | 2 |
| Berlin, C; Feig, PU; Petzinna, D; Ratzmann, KP; Rybka, J; Schernthaner, G; Segal, P | 1 |
| Barzilai, N; Chen, W; Hawkins, M; Hu, M; Liu, R; Rossetti, L | 1 |
| Coniff, RF; Davidson, JA; Feig, PU; Haffner, SM; Johnston, PS; Krol, A | 1 |
| Coniff, RF; Feig, PU; Johnston, PS; Kelley, DE; Krol, A; Mooradian, AD | 1 |
| Coniff, RF; Johnston, PS; Lebovitz, HE; Munera, CL; Raskin, P; Simonson, DC | 1 |
| Baron, AD; Shankar, RR; Zhu, JS | 1 |
| Bauer, RJ; Mitrakou, A; Raptis, AE; Raptis, SA; Schulz, H; Tountas, N | 1 |
| Chiasson, JL; Rabasa-Lhoret, R | 1 |
| Lardinois, CK | 1 |
| Hussain, MA | 1 |
| Axen, KV; Li, X; Sclafani, A | 1 |
| Dylewicz, P; Nowak, A; Przywarska, I; Rychlewski, T; Szcześniak, L | 1 |
| Carter, L; Ciaraldi, TP; Henry, RR; McClain, DA; Mudaliar, S; Nikoulina, S | 1 |
| Andres, E; Blicklé, JF; Brogard, JM | 1 |
| Federici, M; Giaccari, A; Giovannone, B; Hribal, ML; Lauro, D; Lauro, R; Morviducci, L; Pastore, L; Sesti, G; Tamburrano, G | 1 |
| Riddle, MC | 1 |
| Scott, LJ; Spencer, CM | 1 |
| Stadler, HJ | 1 |
| Kuritzky, L; Quillen, DM; Samraj, G | 1 |
| Carlson, RF | 1 |
| Hanefeld, M; Naditch, L; Raptis, SA; Rybka, J; Schernthaner, G; Standl, E | 1 |
| Chiasson, JL; Naditch, L | 1 |
| Laws, A | 1 |
| Maislos, M; Rybka, J; Schernthaner, G; Segal, P; Van Gaal, L | 1 |
| Lefèbvre, PJ; Scheen, AJ | 1 |
| Feng, Y; Keller, H; Mall, C; van Der Woude, F; Yard, B | 1 |
| Badet, B; Badet-Denisot, MA; Leriche, C; Obmolova, G; Teplyakov, A | 1 |
| Neye, H | 1 |
| Kingma, PJ; Menheere, PP; Nieuwenhuijzen Kruseman, AC; Sels, JP | 1 |
| Ahrens, K; Arends, J; Lübke, D; Willms, B | 1 |
| Holman, RR; Steemson, J; Turner, RC | 1 |
| Bloom, SR; Requejo, F; Uttenthal, LO | 1 |
| Klauser, RM; Prager, RJ; Schernthaner, G; Schnack, C; Schneider, BG; Winkler, J | 1 |
| Heinz, G; Komjati, M; Korn, A; Waldhäusl, W | 1 |
| Hillebrand, I; Omar, MA; Seedat, MA | 1 |
| Scott, AR; Tattersall, RB | 1 |
| Alberti, KG; Samad, AH; Taylor, R; Ty Willing, TS | 1 |
| Federlin, K; Hillebrand, I; Laube, H | 1 |
| Bam, WJ; Joubert, PH; Manyane, N | 1 |
| Luger, A; Röggla, G; Schernthaner, G; Schnack, C | 1 |
| Anastasopoulou, K; Frangaki, D; Hillebrand, I; Katsilambros, N; Marangos, M; Philippides, P; Protopapas, J; Siskoudis, P; Toskas, A; Xefteri, H | 1 |
| Arends, J; Willms, BH | 1 |
16 review(s) available for glucosamine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Reappraisal of the pharmacologic approach to treatment of type 2 diabetes mellitus.
Topics: Administration, Oral; Antihypertensive Agents; Biguanides; Diabetes Mellitus, Type 2; Glucosamine; Hormone Replacement Therapy; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Insulin Resistance; Sulfonylurea Compounds; Thiazoles | 2002 |
Therapeutic options for the management of type 2 diabetes mellitus.
Topics: 1-Deoxynojirimycin; Adult; Diabetes Mellitus, Type 2; Disease Management; Education, Medical, Continuing; Education, Pharmacy, Continuing; Glucosamine; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Insulin Aspart; Managed Care Programs; Metformin; Thiazoles; Thiazolidinediones; United States | 2002 |
Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus?
Topics: 1-Deoxynojirimycin; Acarbose; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Inositol; Randomized Controlled Trials as Topic | 2003 |
Treating diabetes using oral agents.
Topics: Administration, Oral; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosamine; Humans; Hypoglycemic Agents; Life Style; Piperidines; Sulfonylurea Compounds; Thiazolidinediones | 2003 |
[Continuation 50. Type 2 diabetes: possibilities and limitations of pharmacological therapy].
Topics: 1-Deoxynojirimycin; Acarbose; Aged; Blood Glucose; Carbamates; Contraindications; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Fasting; Follow-Up Studies; Germany; Glucosamine; Glyburide; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Imino Pyranoses; Insulin; Metformin; Middle Aged; Nateglinide; Obesity; Patient Compliance; Phenylalanine; Pioglitazone; Piperidines; Practice Guidelines as Topic; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors | 2003 |
Alpha-glucosidase inhibitors for type 2 diabetes mellitus.
Topics: 1-Deoxynojirimycin; Acarbose; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Inositol; Randomized Controlled Trials as Topic | 2005 |
Clinical inquiries: Do glucosamine and chondroitin worsen blood sugar control in diabetes?
Topics: Blood Glucose; Chondroitin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Evidence-Based Medicine; Glucosamine; Glycated Hemoglobin; Humans; Nonprescription Drugs; Osteoarthritis; Randomized Controlled Trials as Topic; Reference Values | 2006 |
Potential of alpha-glucosidase inhibitors in elderly patients with diabetes mellitus and impaired glucose tolerance.
Topics: 1-Deoxynojirimycin; Acarbose; Aged; Body Weight; Cognition; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glucosamine; Glucose Intolerance; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Trisaccharides | 1998 |
Type 2 diabetes: glycemic targets and oral therapies for older patients.
Topics: 1-Deoxynojirimycin; Acarbose; Age Factors; Aged; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Glucosamine; Humans; Hypoglycemic Agents; Imino Pyranoses; Metformin; Piperidines; Sulfonylurea Compounds; Trisaccharides | 1998 |
A case for glucosamine.
Topics: Animals; Diabetes Mellitus, Type 2; Glucosamine; Humans; Insulin Resistance; Signal Transduction | 1998 |
[Current status of the treatment of type 2 diabetes mellitus. Alpha-glucosidase inhibitors].
Topics: 1-Deoxynojirimycin; Acarbose; Blood Glucose; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Disaccharides; Drug Combinations; Enzyme Inhibitors; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Hydrolysis; Hypoglycemic Agents; Imino Pyranoses; Insulin; Polysaccharides | 1999 |
Oral pharmacologic management of type 2 diabetes.
Topics: 1-Deoxynojirimycin; Acarbose; Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Metformin; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; United States | 1999 |
Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus.
Topics: 1-Deoxynojirimycin; Biological Availability; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Glucosamine; Glucosidases; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Imino Pyranoses; Intestinal Absorption; Liver; Postprandial Period; Randomized Controlled Trials as Topic; Tissue Distribution | 2000 |
Improving management of type 2 diabetes mellitus: 1. alpha-Glucosidase inhibitors.
Topics: 1-Deoxynojirimycin; Acarbose; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Imino Pyranoses | 1999 |
From Lobry de Bruyn to enzyme-catalyzed ammonia channelling: molecular studies of D-glucosamine-6P synthase.
Topics: Ammonia; Animals; Catalysis; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Escherichia coli; Fungi; Glucosamine; Glucose; Glucose-6-Phosphate; Glutamine; Glutamine-Fructose-6-Phosphate Transaminase (Isomerizing); Humans; Hydrolysis; Mice; Molecular Structure; Nitrogen; Protein Conformation; Rats; Structure-Activity Relationship | 2002 |
[Reducing postprandial glucose levels. Glucosidase antagonists].
Topics: 1-Deoxynojirimycin; Acarbose; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glucosamine; Glucosidases; Humans; Hypoglycemic Agents; Imino Pyranoses; Postprandial Period | 2002 |
31 trial(s) available for glucosamine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Dose-dependent efficacy of miglitol, an alpha-glucosidase inhibitor, in type 2 diabetic patients on diet alone: results of a 24-week double-blind placebo-controlled study.
Topics: 1-Deoxynojirimycin; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Female; Food; Gastrointestinal Diseases; Glucosamine; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Male; Middle Aged; Placebos | 2002 |
The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.
Topics: 1-Deoxynojirimycin; Adult; Aged; Appetite; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucosamine; Humans; Hypoglycemic Agents; Imino Pyranoses; Middle Aged; Obesity; Peptide Fragments; Postprandial Period; Protein Precursors | 2002 |
HbA(1c) and glycemic profile, basal- and post-treatment with Miglitol, in an area with a Mediterranean diet.
Topics: 1-Deoxynojirimycin; Blood Glucose; Diabetes Mellitus, Type 2; Diet; Diet, Diabetic; Fasting; Glucosamine; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Mediterranean Region; Postprandial Period; Regression Analysis | 2002 |
The effect of glucosamine-chondroitin supplementation on glycosylated hemoglobin levels in patients with type 2 diabetes mellitus: a placebo-controlled, double-blinded, randomized clinical trial.
Topics: Aged; Analysis of Variance; Blood Glucose; Chondroitin; Diabetes Mellitus, Type 2; Dietary Supplements; Double-Blind Method; Female; Glucosamine; Glycated Hemoglobin; Humans; Male; Osteoarthritis; Statistics, Nonparametric | 2003 |
The effect of glucosamine on Serum HDL cholesterol and apolipoprotein AI levels in people with diabetes.
Topics: Aged; Apolipoprotein A-I; Blood Glucose; Cholesterol, HDL; Cross-Over Studies; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dietary Supplements; Double-Blind Method; Female; Glucosamine; Humans; Hypolipidemic Agents; Male; Middle Aged | 2007 |
Comparison of miglitol and glibenclamide in diet-treated type 2 diabetic patients.
Topics: 1-Deoxynojirimycin; Blood Glucose; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Diet, Diabetic; Double-Blind Method; Enzyme Inhibitors; Female; Glucosamine; Glyburide; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Male; Middle Aged; Multivariate Analysis; Time Factors; Treatment Failure; Triglycerides | 1995 |
Effect of miglitol (BAY m-1099) on fasting blood glucose in type 2 diabetes mellitus.
Topics: 1-Deoxynojirimycin; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Imino Pyranoses; Male; Middle Aged | 1994 |
Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients.
Topics: 1-Deoxynojirimycin; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosamine; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Lipids; Male; Middle Aged; Time Factors | 1994 |
Does suppression of postprandial blood glucose excursions by the alpha-glucosidase inhibitor miglitol improve insulin sensitivity in diet-treated type II diabetic patients?
Topics: 1-Deoxynojirimycin; Biomarkers; Blood Glucose; Cholesterol; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Diabetic; Double-Blind Method; Enzyme Inhibitors; Female; Fructosamine; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Imino Pyranoses; Insulin; Male; Metabolic Clearance Rate; Middle Aged; Triglycerides | 1996 |
The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone.
Topics: 1-Deoxynojirimycin; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diarrhea; Diet, Diabetic; Double-Blind Method; Enzyme Inhibitors; Fasting; Female; Flatulence; Glucosamine; Glyburide; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Imino Pyranoses; Male; Middle Aged; Placebos; Postprandial Period | 1997 |
Long-term titrated-dose alpha-glucosidase inhibition in non-insulin-requiring Hispanic NIDDM patients.
Topics: 1-Deoxynojirimycin; Albuminuria; Blood Glucose; Creatinine; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Evaluation; Enzyme Inhibitors; Female; Glucosamine; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Hispanic or Latino; Humans; Imino Pyranoses; Insulin; Lipids; Male; Middle Aged; Placebos; Postprandial Period; Time Factors; Treatment Outcome | 1998 |
Chronic treatment of African-American type 2 diabetic patients with alpha-glucosidase inhibition.
Topics: 1-Deoxynojirimycin; Black People; Blood Glucose; Cholesterol, LDL; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Evaluation; Enzyme Inhibitors; Female; Glucosamine; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Male; Middle Aged; Placebos; Postprandial Period; Single-Blind Method; Sulfonylurea Compounds; Treatment Outcome; Triglycerides | 1998 |
Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients.
Topics: 1-Deoxynojirimycin; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Enzyme Inhibitors; Fasting; Female; Food; Glucosamine; Glyburide; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Kinetics; Male | 1998 |
Long-term effectiveness of a new alpha-glucosidase inhibitor (BAY m1099-miglitol) in insulin-treated type 2 diabetes mellitus.
Topics: 1-Deoxynojirimycin; Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Enzyme Inhibitors; Fasting; Female; Follow-Up Studies; Glucosamine; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Male; Middle Aged; Postprandial Period; Time Factors | 1998 |
Glucosamine levels in people with ischaemic heart disease with and without type II diabetes.
Topics: Adult; C-Peptide; Cholesterol; Diabetes Mellitus, Type 2; Glucosamine; Humans; Insulin; Insulin Resistance; Male; Middle Aged; Myocardial Infarction; Statistics, Nonparametric; Triglycerides | 1998 |
[Alpha-glucosidase inhibitor for type 2 diabetic patients. Clinical study with miglitol].
Topics: 1-Deoxynojirimycin; Diabetes Mellitus, Type 2; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin Resistance | 2000 |
Improved glycaemic control with miglitol in inadequately-controlled type 2 diabetics.
Topics: 1-Deoxynojirimycin; Analysis of Variance; Blood Glucose; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Diabetic; Double-Blind Method; Drug Therapy, Combination; Female; Glucosamine; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Imino Pyranoses; Male; Metformin; Middle Aged; Placebos | 2001 |
The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes.
Topics: 1-Deoxynojirimycin; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Fasting; Female; Glucosamine; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Male; Metformin; Middle Aged; Placebos; Postprandial Period; Racial Groups | 2001 |
Miglitol combined with metformin improves glycaemic control in type 2 diabetes.
Topics: 1-Deoxynojirimycin; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Glucosamine; Humans; Hypoglycemic Agents; Imino Pyranoses; Male; Metformin; Middle Aged; Single-Blind Method | 2001 |
alpha-Glucosidase inhibition by miglitol in NIDDM patients.
Topics: 1-Deoxynojirimycin; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Diet, Diabetic; Dietary Carbohydrates; Fatty Acids, Nonesterified; Female; Glucosamine; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Imino Pyranoses; Insulin; Male; Middle Aged | 1992 |
[Delayed absorption of carbohydrates in the therapy of Type II diabetes: comparison between dietary (Muesli) and pharmacological (Alpha-glucosidase inhibition) modification].
Topics: 1-Deoxynojirimycin; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diet, Diabetic; Dietary Carbohydrates; Dietary Fiber; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Imino Pyranoses; Intestinal Absorption; Middle Aged | 1991 |
Post-prandial glycaemic reduction by an alpha-glucosidase inhibitor in type 2 diabetic patients with therapeutically attained basal normoglycaemia.
Topics: 1-Deoxynojirimycin; Biomarkers; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Diet, Diabetic; Eating; Female; Fructosamine; Glucosamine; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Hexosamines; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Insulin, Long-Acting; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Reference Values; Time Factors; Triglycerides | 1991 |
Effects of alpha-glucosidase inhibition and viscous fibre on diabetic control and postprandial gut hormone responses.
Topics: 1-Deoxynojirimycin; Adult; Aged; Biomarkers; Blood Glucose; Cholesterol; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dietary Fiber; Double-Blind Method; Eating; Female; Fructosamine; Galactans; Glucosamine; Glycoside Hydrolase Inhibitors; Hexosamines; Humans; Imino Pyranoses; Male; Mannans; Middle Aged; Plant Gums; Random Allocation; Triglycerides | 1990 |
Effects of 8-wk alpha-glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled type II diabetic patients.
Topics: 1-Deoxynojirimycin; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Imino Pyranoses; Insulin; Liver; Male; Middle Aged | 1989 |
Reduction of postprandial blood glucose by the alpha-glucosidase inhibitor Miglitol (BAY m 1099) in type II diabetes.
Topics: 1-Deoxynojirimycin; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diet; Dose-Response Relationship, Drug; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Imino Pyranoses; Insulin; Middle Aged; Time Factors | 1989 |
The clinical efficacy of a second-generation alpha-glucosidase inhibitor in non-insulin-dependent diabetic patients.
Topics: 1-Deoxynojirimycin; Adult; Anti-Bacterial Agents; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosamine; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Male; Middle Aged; Random Allocation; Sulfonylurea Compounds | 1987 |
Alpha glucosidase inhibition in the treatment of non-insulin-dependent diabetes mellitus.
Topics: 1-Deoxynojirimycin; Adult; Aged; Blood Glucose; Carbohydrate Metabolism; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Imino Pyranoses; Insulin; Intestinal Absorption; Middle Aged; Random Allocation | 1988 |
Effects of BAYm 1099, new alpha-glucosidase inhibitor, on acute metabolic responses and metabolic control in NIDDM over 1 mo.
Topics: 1-Deoxynojirimycin; 3-Hydroxybutyric Acid; Alanine; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Eating; Fatty Acids, Nonesterified; Female; Glucosamine; Glycerol; Glycoside Hydrolase Inhibitors; Humans; Hydroxybutyrates; Hypoglycemic Agents; Imino Pyranoses; Insulin; Lactates; Male; Middle Aged; Pyruvates | 1988 |
Effects of the alpha-glucosidase inhibitor 1 desoxynojirimycin (Bay m 1099) on postprandial blood glucose, serum insulin and C-peptide levels in type II diabetic patients.
Topics: 1-Deoxynojirimycin; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Eating; Female; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Imino Pyranoses; Insulin; Male; Middle Aged; Obesity; Pancreatic Hormones | 1986 |
A double-blind study on the efficacy and tolerance of a new alpha-glucosidase inhibitor in type-2 diabetics.
Topics: 1-Deoxynojirimycin; Adult; Aged; Anti-Bacterial Agents; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Tolerance; Female; Glucosamine; Humans; Imino Pyranoses; Male; Middle Aged; Random Allocation | 1986 |
Smoothing effect of a new alpha-glucosidase inhibitor BAY m 1099 on blood glucose profiles of sulfonylurea-treated type II diabetic patients.
Topics: 1-Deoxynojirimycin; Adult; Blood Glucose; Circadian Rhythm; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Imino Pyranoses; Male; Middle Aged; Sulfonylurea Compounds | 1986 |
34 other study(ies) available for glucosamine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
The role of type 2 diabetes in the association between habitual glucosamine use and dementia: a prospective cohort study.
Topics: Dementia; Diabetes Mellitus, Type 2; Glucosamine; Humans; Incidence; Prospective Studies; Risk Factors | 2022 |
Glucosamine effects on platelet aggregation of type 2 diabetes mellitus patients: in vitro assays.
Topics: Animals; Blood Platelets; Diabetes Mellitus, Type 2; Glucosamine; Platelet Aggregation; Platelet Aggregation Inhibitors; Thrombin | 2023 |
Glucosamine Use, Inflammation, and Genetic Susceptibility, and Incidence of Type 2 Diabetes: A Prospective Study in UK Biobank.
Topics: Adult; Aged; Aged, 80 and over; Biological Specimen Banks; C-Reactive Protein; Diabetes Mellitus, Type 2; Dietary Supplements; Female; Follow-Up Studies; Genetic Predisposition to Disease; Glucosamine; Humans; Incidence; Inflammation; Male; Middle Aged; Polymorphism, Single Nucleotide; Prospective Studies; Risk Factors; United Kingdom; Young Adult | 2020 |
Native Collagen II Relieves Bone Impairment through Improving Inflammation and Oxidative Stress in Ageing db/db Mice.
Topics: Aging; Animals; Bone Density; Bone Resorption; Chondroitin Sulfates; Collagen Type II; Diabetes Mellitus, Type 2; Gene Expression Regulation; Glucosamine; Humans; Inflammation; Interleukin-1beta; Mice; Mice, Inbred NOD; Oxidative Stress; RANK Ligand; Tartrate-Resistant Acid Phosphatase | 2021 |
Hypoglycemic effect of deoxynojirimycin-polysaccharide on high fat diet and streptozotocin-induced diabetic mice via regulation of hepatic glucose metabolism.
Topics: 1-Deoxynojirimycin; Animals; Blood Glucose; Blotting, Western; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fructose-Bisphosphatase; Glucokinase; Glucosamine; Glucose-6-Phosphatase; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Mice; Mice, Inbred ICR; Phosphoenolpyruvate Carboxykinase (ATP); Phosphofructokinase-1, Liver Type; Pyruvate Carboxylase; Pyruvate Decarboxylase; Random Allocation | 2015 |
Concurrently using rosiglitazone prevents glucosamine-induced islet beta-cell apoptosis and dysfunction.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; Diabetes Mellitus, Type 2; Gene Expression; Glucosamine; Humans; Insulin-Secreting Cells; Proto-Oncogene Proteins c-bcl-2; Rats; Rosiglitazone; Thiazolidinediones | 2010 |
[Therapy decision based on the glucose triad. Drug treatment of type 2 diabetes].
Topics: 1-Deoxynojirimycin; Acarbose; Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Glucosamine; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Insulin Resistance; Insulin Secretion; Metformin; Obesity; Pioglitazone; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Time Factors | 2003 |
[Usefulness of miglitol in patients with diabetes mellitus type 2 and insufficient control of the blood glucose].
Topics: 1-Deoxynojirimycin; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Glucosamine; Humans; Hyperlipidemias; Hypoglycemic Agents; Imino Pyranoses; Lipids; Male; Middle Aged; Treatment Outcome | 2004 |
Can glucosamine supplements be applied for all patients with type 2 diabetes with osteoarthritis?
Topics: Blood Glucose; Chondroitin; Diabetes Mellitus, Type 2; Dietary Supplements; Glucosamine; Glycated Hemoglobin; Humans; Osteoarthritis | 2004 |
[Treatment of type 2 diabetes mellitus with the alpha-glucosidase inhibitor Miglitol in the doctor's office].
Topics: 1-Deoxynojirimycin; Adult; Age Factors; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Family Practice; Feasibility Studies; Female; Follow-Up Studies; Glucosamine; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Imino Pyranoses; Internal Medicine; Male; Middle Aged; Patient Compliance; Risk Factors; Sex Factors; Time Factors; Treatment Outcome; Weight Loss | 2000 |
[The alpha-glucosidase inhibitor miglitol for the treatment of type 2 diabetes mellitus in the doctor's office].
Topics: 1-Deoxynojirimycin; Adult; Aged; Aged, 80 and over; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosamine; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Male; Middle Aged; Safety; Time Factors; Triglycerides | 2001 |
[Pharmacokinetic, pharmacological, and clinical profile of miglitol (SEIBULE), a novel alpha-glucosidase inhibitor].
Topics: 1-Deoxynojirimycin; Animals; Diabetes Mellitus, Type 2; Dogs; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Rats | 2006 |
Is further research needed on glucosamine?
Topics: Blood Glucose; Chondroitin; Diabetes Mellitus, Type 2; Endothelium, Vascular; Glucosamine; Homeostasis; Humans; Osteoarthritis; Research | 2007 |
Proteomic analysis of O-GlcNAc modifications derived from streptozotocin and glucosamine induced beta-cell apoptosis.
Topics: Acetylglucosamine; Animals; Apoptosis; Cell Line; Diabetes Mellitus, Type 2; Glucosamine; Glycosylation; Insulin; Insulin Secretion; Insulin-Secreting Cells; Models, Biological; Oximes; Phenylcarbamates; Proteomics; Proto-Oncogene Proteins c-akt; Rats; Signal Transduction; Streptozocin | 2007 |
Supplementation of a novel microbial biopolymer, PGB1, from new Enterobacter sp. BL-2 delays the deterioration of type 2 diabetic mice.
Topics: Animals; Biopolymers; Blood Glucose; Diabetes Mellitus, Type 2; Dietary Supplements; Enterobacter; Glucosamine; Glucose Tolerance Test; Hypoglycemic Agents; Immunohistochemistry; Insulin; Liver Glycogen; Male; Mice; Mice, Inbred C57BL; Pancreas; Random Allocation; Rosiglitazone; Thiazolidinediones | 2007 |
Glucosamine inhibits glucokinase in vitro and produces a glucose-specific impairment of in vivo insulin secretion in rats.
Topics: Animals; Arginine; Diabetes Mellitus, Type 2; Glucokinase; Glucosamine; Glucose; Humans; In Vitro Techniques; Infusions, Intravenous; Islets of Langerhans; Kinetics; Male; Rats; Rats, Sprague-Dawley | 1994 |
The effects of the intestinal glucosidase inhibitory BAY M 1099 (miglitol) on glycemic status of obese-diabetic rats.
Topics: 1-Deoxynojirimycin; Animals; Blood Glucose; Body Weight; Diabetes Mellitus; Diabetes Mellitus, Type 2; Eating; Glucosamine; Glycoside Hydrolase Inhibitors; Imino Pyranoses; Male; Obesity; Rats; Rats, Inbred SHR | 1993 |
In vitro study of the effect of miglitol on carbohydrate digestion and intestinal metabolism in normal and non-insulin-dependent diabetic rats.
Topics: 1-Deoxynojirimycin; Animals; Carbohydrate Metabolism; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucosamine; Glycoside Hydrolase Inhibitors; Imino Pyranoses; In Vitro Techniques; Intestinal Absorption; Intestine, Small; Male; Perfusion; Rats; Rats, Wistar | 1996 |
Role of the glucosamine pathway in fat-induced insulin resistance.
Topics: Animals; Diabetes Mellitus, Type 2; Fatty Acids; Fructosephosphates; Glucosamine; Glucose; Glucose-6-Phosphate; Glycogen; Glycolysis; Insulin; Insulin Resistance; Male; Muscle, Skeletal; Phosphorylation; Rats; Rats, Sprague-Dawley; Uridine | 1997 |
Effect of miglitol administration to non-insulin-dependent diabetic rats.
Topics: 1-Deoxynojirimycin; Administration, Oral; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Enzyme Inhibitors; Glucosamine; Hypoglycemic Agents; Imino Pyranoses; Male; Rats; Rats, Wistar | 1998 |
Glucosamine infusion in rats mimics the beta-cell dysfunction of non-insulin-dependent diabetes mellitus.
Topics: Animals; Arginine; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glucosamine; Glucose; Infusions, Intravenous; Insulin; Insulin Secretion; Islets of Langerhans; Male; Rats; Rats, Sprague-Dawley; Time Factors | 1998 |
Miglitol (BAY m 1099) treatment of diabetic hypothalamic-dietary obese rats improves islet response to glucose.
Topics: 1-Deoxynojirimycin; Animal Feed; Animals; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Disease Models, Animal; Female; Glucosamine; Glucose; Glycoside Hydrolase Inhibitors; Hypoglycemic Agents; Imino Pyranoses; Insulin; Insulin Secretion; Islets of Langerhans; Obesity; Rats; Rats, Sprague-Dawley; Ventromedial Hypothalamic Nucleus | 1999 |
Miglitol for type 2 diabetes mellitus.
Topics: 1-Deoxynojirimycin; Diabetes Mellitus, Type 2; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses | 1999 |
Glucosamine regulation of glucose metabolism in cultured human skeletal muscle cells: divergent effects on glucose transport/phosphorylation and glycogen synthase in non-diabetic and type 2 diabetic subjects.
Topics: Adult; Biological Transport; Cells, Cultured; Diabetes Mellitus, Type 2; Glucosamine; Glucose; Glycogen Synthase; Humans; Monosaccharide Transport Proteins; Muscle, Skeletal; Phosphorylation; Reference Values | 1999 |
Evidence for glucose/hexosamine in vivo regulation of insulin/IGF-I hybrid receptor assembly.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucosamine; Insulin; Insulin-Like Growth Factor I; Kinetics; Male; Muscle, Skeletal; Phlorhizin; Protein Multimerization; Rats; Rats, Sprague-Dawley; Receptor, IGF Type 1; Receptor, Insulin; Reference Values | 1999 |
[Drug therapy of type 2 diabetes: insulin sensitizers improve results].
Topics: 1-Deoxynojirimycin; Acarbose; Diabetes Mellitus, Type 2; Diet Therapy; Diet, Diabetic; Drug Therapy, Combination; Glucosamine; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin | 1999 |
[Risk of complications in the diabetic patient. Postprandial blood glucose peaks as deciding factor].
Topics: 1-Deoxynojirimycin; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucosamine; Humans; Hypoglycemic Agents; Imino Pyranoses | 2000 |
Miglitol and hepatotoxicity in type 2 diabetes mellitus.
Topics: 1-Deoxynojirimycin; Acarbose; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Liver; Liver Function Tests; Transaminases | 2000 |
A new era in type 2 diabetes mellitus treatment?
Topics: 1-Deoxynojirimycin; Acarbose; Carbamates; Diabetes Mellitus, Type 2; Glucosamine; Humans; Hypoglycemic Agents; Imino Pyranoses; Multicenter Studies as Topic; Pioglitazone; Piperidines; Randomized Controlled Trials as Topic; Thiazoles; Thiazolidinediones | 2001 |
[Alpha-glucosidase inhibitor in type 2 diabetic patients. Metabolism and body weight are favorably modified].
Topics: 1-Deoxynojirimycin; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Energy Metabolism; Glucosamine; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses | 2001 |
Potential pharmacokinetics interference between alpha-glucosidase inhibitors and other oral antidiabetic agents.
Topics: 1-Deoxynojirimycin; Administration, Oral; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Intestinal Absorption | 2002 |
Influence of high glucose concentrations on the expression of glycosaminoglycans and N-deacetylase/N-sulphotransferase mRNA in cultured skin fibroblasts from diabetic patients with or without nephropathy.
Topics: Aged; Amidohydrolases; Cells, Cultured; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Fibroblasts; Gene Expression; Glucosamine; Glucose; Glycosaminoglycans; Heparan Sulfate Proteoglycans; Humans; Male; Middle Aged; Models, Biological; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Skin; Sulfotransferases | 2002 |
Effect of alpha-inhibitors on blood glucose and insulin levels.
Topics: 1-Deoxynojirimycin; Acarbose; Aged; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Middle Aged; Obesity; Reference Values; Trisaccharides | 1988 |
Effect of an alpha-glucosidase inhibitor (BAY m 1099) on post-prandial blood glucose and insulin in type II diabetics.
Topics: 1-Deoxynojirimycin; Adult; Aged; Anti-Bacterial Agents; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucosamine; Humans; Imino Pyranoses; Insulin; Male; Middle Aged | 1986 |